Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | -1.69% | +2.14% | -62.34% |
May. 31 | Verve Therapeutics Names Troy Lister Chief Scientific Officer | MT |
May. 31 | Verve Therapeutics, Inc. Announces Executive Changes | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.34% | 448M | |
+56.75% | 59.34B | |
+42.78% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+15.64% | 27.26B | |
-21.16% | 19.23B | |
+33.00% | 12.61B | |
+3.25% | 12.49B | |
+26.31% | 12.28B |
- Stock Market
- Equities
- VERV Stock
- News Verve Therapeutics, Inc.
- Guggenheim Adjusts Price Target on Verve Therapeutics to $55 From $56, Maintains Buy Rating